OXFD - Oxford Immunotec Global inks distribution pact with RIKEN Genesis

Oxford Immunotec Global (OXFD) and RIKEN Genesis Co, a subsidiary of The Sysmex Corporation (Sysmex), in Japan come together, where latter will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit, developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells that might offer new insight into immunity to SARS-CoV-2 infection.After following successful trial of the TSPOT Discovery SARS-CoV-2 kit in Japan, Sysmex's T cell response kit will form an important adjunct to the current range of tests for COVID-19.The trial data published by Public Health England using the T-SPOT Discovery SARS-CoV-2 kit suggests that individuals with SARS-CoV-2 specific T cells but without detectible antibodies can be protected from infection.T-SPOT Discovery SARS-CoV-2 kit is available for research use across Europe and the USA and not for use in diagnostic procedures.

For further details see:

Oxford Immunotec Global inks distribution pact with RIKEN Genesis